Does EGFR Mutation Type Influence Patient-Reported Outcomes in Patients with Advanced EGFR Mutation-Positive Non-Small-Cell Lung Cancer? Analysis of Two Large, Phase III Studies Comparing Afatinib with Chemotherapy (LUX-Lung 3 and LUX-Lung 6)

類似資料

• EGFR mutation detection in circulating cell-free DNA of lung adenocarcinoma patients: analysis of LUX-Lung 3 and 6
  著者:: Wu, Yi-Long, 等
  出版事項: (2017)
• Afatinib versus gemcitabine/cisplatin for first-line treatment of Chinese patients with advanced non-small-cell lung cancer harboring EGFR mutations: subgroup analysis of the LUX-Lung 6 trial
  著者:: Wu, Yi-Long, 等
  出版事項: (2018)
• First-line afatinib vs gefitinib for patients with EGFR mutation-positive NSCLC (LUX-Lung 7): impact of afatinib dose adjustment and analysis of mode of initial progression for patients who continued treatment beyond progression
  著者:: Schuler, Martin, 等
  出版事項: (2019)
• Afatinib versus gefitinib in patients with EGFR mutation-positive advanced non-small-cell lung cancer: overall survival data from the phase IIb LUX-Lung 7 trial
  著者:: Paz-Ares, L., 等
  出版事項: (2017)
• Afatinib in lung cancer harboring EGFR mutation in the LUX-Lung trials: six plus three is greater than seven?
  著者:: Mitsudomi, Tetsuya, 等
  出版事項: (2016)